GANX insider trading
NasdaqGM HealthcareGain Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Company website: gaintherapeutics.com
GANX insider activity at a glance
FilingIQ has scored 25 insider transactions for GANX since Aug 16, 2021. The most recent filing in our index is dated Mar 24, 2026.
Across the full history, 11 open-market purchases
and 2 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GANX insider trades is 62.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GANX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for GANX?
- FilingIQ tracks 25 Form 4 insider transactions for GANX (Gain Therapeutics, Inc.), covering filings from Aug 16, 2021 onwards. 2 of those were filed in the last 90 days.
- Are GANX insiders net buyers or net sellers?
- Across the full Form 4 history for GANX, 11 transactions (44%) were open-market purchases and 2 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GANX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is GANX in?
- Gain Therapeutics, Inc. (GANX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $72.69M.
Methodology & sources
Every GANX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.